Harpoon Therapeutics Inc logo

Harpoon Therapeutics Inc Share Price (NASDAQ: HARP)

▲

-23.01

(-100%)

Live

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 8 Mar 2024

Check the interactive Harpoon Therapeutics Inc Stock chart to analyse performance

Harpoon Therapeutics Inc Key Stats

Check Harpoon Therapeutics Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$23.01
Open
$23.0
Market Capitalization
$491.9M
Today's Volume
$6.6M
Revenue TTM
$37.3M
EBITDA
$-35.4M
Earnings Per Share (EPS)
$-8.62
Profit Margin
-81.67%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-284.32%

Global Institutional Holdings in Harpoon Therapeutics Inc

  • Name

    Holdings %

  • Cormorant Asset Management, LLC

    10.98%

  • Franklin Resources Inc

    6.97%

  • Artal Group S A

    6.09%

  • Soleus Capital Management, L.P.

    3.84%

  • MPM Oncology Impact Management LP

    1.49%

  • Mpm Asset Management, LLC

    1.46%

Analyst Recommendation on Harpoon Therapeutics Inc Stock

Rating
Trend

Buy

    75%Buy

    25%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Harpoon Therapeutics Inc(by analysts ranked 0 to 5 stars)

About Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Organization
Harpoon Therapeutics Inc
Employees
53
CEO
Ms. Julie M. Eastland M.B.A.
Industry
Biotechnology

Important FAQs about investing in HARP Stock from India :

What is Harpoon Therapeutics Inc share price today?

Harpoon Therapeutics Inc share price today is as on . Harpoon Therapeutics Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Harpoon Therapeutics Inc share?

Harpoon Therapeutics Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Harpoon Therapeutics Inc stock price today i.e. is trending at , lower by 100% versus the 52 week high.

How to invest in Harpoon Therapeutics Inc Stock (HARP) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Harpoon Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Harpoon Therapeutics Inc Shares .

What is the minimum amount required to buy Harpoon Therapeutics Inc Stock (HARP) from India?

Indian investors can start investing in Harpoon Therapeutics Inc (HARP) shares with as little as ₹88.267 or $1 (as of October 28, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.67 in Harpoon Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on October 28, 2025). Learn more about fractional shares .

What are the returns that Harpoon Therapeutics Inc has given to Indian investors in the last 5 years?

Harpoon Therapeutics Inc stock has given 0.0% share price returns and 18.97% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?